Here are the 10-K annual reports from Exelixis Inc (EXEL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow EXEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EXEL filings page.
Exelixis, Inc. is an oncology-focused biopharma built around its cabozantinib franchise, marketed as CABOMETYX and COMETRIQ for multiple cancers including renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, neuroendocrine tumors and medullary thyroid cancer.
In 2025, Exelixis recorded $2.12 billion in net product revenue from CABOMETYX and COMETRIQ, up about 17% year over year, and earned $179.2 million in cabozantinib royalties from partners Ipsen and Takeda, marking its ninth consecutive profitable year. Collaboration deals generate additional milestones and royalties.
The company remains heavily reliant on CABOMETYX but is building a broad pipeline. Lead candidate zanzalintinib, a next-generation VEGF-receptor TKI, is in multiple late-stage trials across colorectal, renal cell, neuroendocrine tumors and meningioma, with a U.S. NDA accepted for previously treated metastatic colorectal cancer and a PDUFA target date of December 3, 2026.
Additional early-stage programs include small molecule USP1 inhibitor XL309 and several biotherapeutics, such as ADC XB010, bispecific antibody XB628 and TF-targeting ADC XB371. Extensive collaborations with Ipsen, Takeda, Roche, Bristol Myers Squibb, Merck and others support global commercialization of cabozantinib and co-fund development of new regimens.